Related Experiment Video

Updated: Aug 19, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

PLAC test for identification of individuals at increased risk for coronary heart disease

Ron C Hoogeveen1, Christie M Ballantyne

  • 1Baylor College of Medicine, Section of Atherosclerosis & Lipoprotein Research, Department of Medicine, Center for Cardiovascular Disease Prevention, Houston, TX 77030, USA. ronh@bcm.tmc.edu

Expert Review of Molecular Diagnostics
|February 23, 2005
PubMed

Insights

Inflammation plays a key role in cardiovascular disease. A new blood test for lipoprotein-associated phospholipase A(2) (PLAC test) shows promise as a screening tool for identifying individuals at increased risk of coronary heart disease.

Area of Science:

  • Cardiovascular Research
  • Inflammatory Processes in Disease
  • Biomarker Discovery

Background:

  • Cardiovascular disease (CVD) etiology is increasingly linked to inflammatory processes.
  • Novel inflammatory biomarkers are being identified for enhanced CVD risk screening.
  • Lipoprotein-associated phospholipase A(2) (Lp-PLA2) is a key inflammatory marker.

Purpose of the Study:

  • To review the development and efficacy of a new blood test for Lp-PLA2.
  • To evaluate Lp-PLA2 as a predictive biomarker for cardiovascular disease risk.
  • To identify the optimal patient population for this novel screening tool.

Main Methods:

  • Review of recent scientific literature on Lp-PLA2 and cardiovascular risk.
  • Discussion of the US Food and Drug Administration-approved PLAC test.
  • Analysis of the predictive value of Lp-PLA2 for coronary heart disease risk.

Main Results:

  • Lp-PLA2 is a validated inflammatory biomarker for cardiovascular risk.
  • The PLAC test provides a measurable assessment of Lp-PLA2 levels.
  • Evidence supports Lp-PLA2's role in predicting future cardiovascular events.

Conclusions:

  • The PLAC test offers a valuable new tool for cardiovascular risk assessment.
  • Targeted implementation can optimize the benefits of Lp-PLA2 screening.
  • Further research may refine the role of Lp-PLA2 in personalized cardiovascular medicine.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...